Article (Scientific journals)
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes, David; Constantinescu, Catalin; Vrancken, Louise et al.
2022In Journal of Hematology and Oncology, 15 (1), p. 78
Peer Reviewed verified by ORBi
 

Files


Full Text
s13045-022-01296-2.pdf
Author postprint (1.9 MB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adoptive cell therapy; BAT; BiTE; Bispecific T cell engager; Bispecific antibody; Bispecific antibody armed T cell; CAR T; Chimeric antigen receptor; Immunotherapy; Multiple myeloma; Stem cell transplantation; Receptors, Chimeric Antigen; Humans; Immunotherapy, Adoptive; Patient Selection; Multiple Myeloma/drug therapy; Receptors, Chimeric Antigen/therapeutic use; Molecular Biology; Hematology; Oncology; Cancer Research
Abstract :
[en] Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains an incurable disease. Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, SLAMF7 (CS1), GPRC5D, FCRH5 or CD38. However, stem cell transplantation is still indispensable in transplant-eligible patients. Studies suggest that the early use of immunotherapy may improve outcomes significantly. In this review, we summarize the currently available clinical literature on CAR and BiTE in MM. Furthermore, we will compare these two T cell-based immunotherapies and discuss potential therapeutic approaches to promote development of new clinical trials, using T cell-based immunotherapies, even as bridging therapies to a transplant.
Disciplines :
Hematology
Immunology & infectious disease
Laboratory medicine & medical technology
Author, co-author :
Kegyes, David ;  Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania ; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Constantinescu, Catalin ;  Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania ; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania ; Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania
Vrancken, Louise ;  Centre Hospitalier Universitaire de Liège - CHU > > Frais communs médecine - Pool assistants
Rasche, Leo;  Department of Internal Medicine II, University of Würzburg, Würzburg, Germany
Grégoire, Céline  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Tigu, Bogdan;  Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Gulei, Diana;  Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania ; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Dima, Delia;  Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania
Tanase, Alina;  Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Einsele, Hermann;  Department of Internal Medicine II, University of Würzburg, Würzburg, Germany
Ciurea, Stefan;  Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, USA
Tomuleasa, Ciprian;  Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ciprian.tomuleasa@umfcluj.ro ; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ciprian.tomuleasa@umfcluj.ro ; Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania. ciprian.tomuleasa@umfcluj.ro
Caers, Jo  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
More authors (3 more) Less
 These authors have contributed equally to this work.
Language :
English
Title :
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Publication date :
07 June 2022
Journal title :
Journal of Hematology and Oncology
eISSN :
1756-8722
Publisher :
BioMed Central Ltd, England
Volume :
15
Issue :
1
Pages :
78
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
The laboratory of Hematology (University of Liège) is supported by the Foundation Against Cancer, the CHU de Liège, the Fonds National de la Recherche Scientifique (F.N.R.S., Belgium), The Foundation Léon Frédéricq and the Fonds spéciaux de la Recherche (University of Liege). This work is granted by project PDI-PFE-CDI 2021, entitled Increasing the Performance of Scientific Research, Supporting Excellence in Medical Research, and Innovation, PROGRES, no. 40PFE/30.12.2021.David Kegyes and Catalin Constantinescu contributed equally to the current manuscript and are both considered first author. David Kegyes is funded by an internal grant of the Iuliu Hatieganu University – School of Medicine. This manuscript is also the result of a grant PN-III-CEI-BIM-PBE-2020-0016 within PNCDI I—collaboration between Romania and Belgium (Wallonia), contract number 13-BM/2020. Ciprian Tomuleasa is also supported by 3 grants awarded by the Romanian National Ministry of Research, Innovation and Digitalization: CCCDI-UEFISCDI, Project No. PN-III-P4-ID-PCCF-2016–0112 within PNCDI III, for Young Research Teams 2020–2022 (Grant No. PN-III-P1-1.1-TE-2019-0271); PN-III-P4-ID-PCE-2020-1118 within PNCDI IV, Projects for Exploratory Medicine; Projects for Exploratory Medicine—PCE 225/2021; Diana Gulei is supported by 2 grants: one awarded by the Romanian National Ministry of Research, Innovation and Digitalization: Postdoctoral Research Project PN-III-P1-1.1-PD-2019-0805, No. PD122/2020; as well as an international collaborative grant of the European Economic Space between Romania and Iceland 2021–2023: “Cooperation strategy for knowledge transfer, internationalization and curricula innovation in the field of research education at the 3rd level of study –AURORA.” The laboratory of Hematology (University of Liège) was supported by the Foundation Against Cancer, the CHU de Liège, the Fonds National de la Recherche Scientifique (F.N.R.S., Belgium), The Foundation Léon Frédéricq and the Fonds spéciaux de la Recherche (University of Liege). The authors thank Carole Kay for proofreading and correcting our manuscript.
Available on ORBi :
since 31 August 2022

Statistics


Number of views
112 (3 by ULiège)
Number of downloads
37 (1 by ULiège)

Scopus citations®
 
17
Scopus citations®
without self-citations
13
OpenCitations
 
1

Bibliography


Similar publications



Contact ORBi